TNFRSF14 Antibody
Code | Size | Price |
---|
PSI-3773-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3773-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
TNFRSF14 Antibody: TR2, ATAR, HVEA, HVEM, CD270, LIGHTR, UNQ329/PRO509, Tumor necrosis factor receptor superfamily member 14, Herpes virus entry mediator A, Herpesvirus entry mediator A
Application Note:
TNFRSF14 antibody can be used for the detection of TNFRSF14 by Western blot at 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
TNFRSF14 Antibody: Tumor necrosis factor receptor (TNFR) superfamily members are defined by cysteine-rich domains in their extracellular regions that bind TNF-related ligands that share a common structural homology in their extracellular domain. TNFRSF14 was initially identified as the Herpesvirus entry mediator and upon binding to the herpes simplex virus (HSV) envelope glycoprotein D or either of its natural ligands LIGHT and lymphotoxin alpha (LT), activates the transcription factors NF-κB and AP-1. Activation of this signal transduction pathway in T cells stimulates T cell proliferation and cytokine production, leading to inflammation and enhanced CTL-mediated tumor immunity, suggesting that these proteins may be useful as potential targets for controlling cellular immune responses.
Background References:
- Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 2005; 23:23-68.
- Montgomery RI, Warner MS, Lum BJ, et al. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87:427-36.
- Marsters SA, Ayres TM, Skubatch M, et al. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J. Biol. Chem.1997; 272:14029-32.
- Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8:21-30.
Buffer:
TNFRSF14 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
TNFRSF14 antibody was raised against a 16 amino acid synthetic peptide from near the carboxy terminus of human TNFRSF14.
The immunogen is located within the last 50 amino acids of TNFRSF14.
The immunogen is located within the last 50 amino acids of TNFRSF14.
NCBI Gene ID #:
8764
NCBI Official Name:
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)
NCBI Official Symbol:
TNFRSF14
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
Q92956
Protein GI Number:
13878821
Purification:
TNFRSF14 Antibody is affinity chromatography purified via peptide column.
Research Area:
Herpes,Chemokines & Cytokines,Infectious Disease
Swissprot #:
Q92956
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | TNFRSF14 Peptide | PSI-3773P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|